Company Team Search Site Map Careers Privacy Statement
:: Home
:: About Us
:: R&D
:: Products
:: Services
:: Infrastucture
:: Contact us
Virchow Products
Products

NAME

GENERIC NAME

THERAPEUTIC AREA

CE APPROVED

USFDA 510(k) APPROVED

DCGI APPROVED

IONSIL

Silver Nitrate Gel

Woundcare & Haemostasis

BIOZEL

Sodium Hyaluronate Cream

Woundcare & Haemostasis

IN PROCESS

ALGINET

Calcium Alginate Fibre Fleece

Woundcare & Haemostasis

SCARAZE

Stretch Marks Cream

Woundcare & Haemostasis

DEBRIDACE

Papain Urea Ointment

Woundcare & Haemostasis

HEALACE

Recombinant Human Platelet Derived Growth Factor- BB Gel

Woundcare & Haemostasis

GELSORB

Absorbable Gelatin Sponge

Woundcare & Haemostasis

SAP THERAPY

Negative Pressure Wound Vacuum

Woundcare & Haemostasis

HYFIL

Sodium Hyaluronate Sterile Injection Dermal

Woundcare & Haemostasis

HYOPT/ HYOPT PLUS

Sodium Hyaluronate Ophthalmology

Ophthalmology

OSTEOTIDE

Teriparatide (r-Human Parathyroid Hormone Injection)

Orthopaedics

HYORTH/ HYORTH XL

Sodium Hyaluronate Sterile Injection Orthopaedic

Orthopaedics

TUFPRO

Bacillus Clausii Spores Suspension

Probiotic

INFERON

Recombinant Human Interferon alpha-2b Injection

Gastroenterology

VIPEG

Pegylated Interferon alpha-2b

Gastroenterology

*Hyorth, Hyorth XL, Hyopt Plus and Ionsil are currently under registration in the UAE.


News & Events

Virchow Biotech is filing for U.S.Food and Drug administration’s (FDA) approval for its in house developed advanced wound care products.

Virchow Biotech received Drug control’s (DCGI) approval for conducting clinical trials on periogen, an indigenously developed recombinant therapeutic product for periodontal diseases

Virchow Biotech and Ranbaxy signed an MOU to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment. We are the first in the world to launch this biogeneric product